Literature DB >> 29776742

Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.

Matthew W Martin1, Jennifer Y Lee2, David R Lancia2, Pui Yee Ng2, Bingsong Han2, Jennifer R Thomason2, Maureen S Lynes2, C Gary Marshall2, Chiara Conti2, Alan Collis2, Monica Alvarez Morales2, Kshama Doshi2, Aleksandra Rudnitskaya2, Lili Yao3, Xiaozhang Zheng2.   

Abstract

N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool to study the biology of HDAC11 and its potential use as a therapeutic target for oncology and inflammation indications.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HDAC11; HDACs; Hydroxamic acid; Inflammation; Isoindoline; Oncology

Mesh：

Substances：

Year:  2018        PMID： 29776742     DOI： 10.1016/j.bmcl.2018.05.021

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  10 in total

1.  Activity-Guided Design of HDAC11-Specific Inhibitors.

Authors:  Se In Son; Ji Cao; Cheng-Liang Zhu; Seth P Miller; Hening Lin
Journal:  ACS Chem Biol       Date:  2019-07-02       Impact factor: 5.100

2.  Garcinol Is an HDAC11 Inhibitor.

Authors:  Se In Son; Dan Su; Thanh Tu Ho; Hening Lin
Journal:  ACS Chem Biol       Date:  2020-10-09       Impact factor: 5.100

3.  A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway.

Authors:  Po-Yuan Huang; I-An Shih; Ying-Chih Liao; Huey-Ling You; Ming-Jen Lee
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

4.  HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Authors:  Lanzhu Yue; Vasundhara Sharma; Nathan P Horvat; Afua A Akuffo; Matthew S Beatty; Cem Murdun; Christelle Colin; Julia M R Billington; William E Goodheart; Eva Sahakian; Ling Zhang; John J Powers; Narmin E Amin; Que T Lambert-Showers; Lancia N Darville; Javier Pinilla-Ibarz; Gary W Reuther; Kenneth L Wright; Chiara Conti; Jennifer Y Lee; Xiaozhang Zheng; Pui Yee Ng; Matthew W Martin; C Gary Marshall; John M Koomen; Ross L Levine; Amit Verma; H Leighton Grimes; Eduardo M Sotomayor; Zonghong Shao; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

Review 5.  Therapeutic targets for cardiac fibrosis: from old school to next-gen.

Authors:  Joshua G Travers; Charles A Tharp; Marcello Rubino; Timothy A McKinsey
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

6.  Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling.

Authors:  Rushita A Bagchi; Emma L Robinson; Tianjing Hu; Ji Cao; Jun Young Hong; Charles A Tharp; Hanan Qasim; Kathleen M Gavin; Julie Pires da Silva; Jennifer L Major; Bradley K McConnell; Edward Seto; Hening Lin; Timothy A McKinsey
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-15       Impact factor: 12.779

7.  First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement.

Authors:  Daniel Herp; Johannes Ridinger; Dina Robaa; Stephen A Shinsky; Karin Schmidtkunz; Talha Z Yesiloglu; Theresa Bayer; Raphael R Steimbach; Corey J Herbst-Gervasoni; Annika Merz; Christophe Romier; Peter Sehr; Nikolas Gunkel; Aubry K Miller; David W Christianson; Ina Oehme; Wolfgang Sippl; Manfred Jung
Journal:  Chembiochem       Date:  2022-06-10       Impact factor: 3.461

8.  Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.

Authors:  Namrata Bora-Singhal; Durairaj Mohankumar; Biswarup Saha; Christelle M Colin; Jennifer Y Lee; Matthew W Martin; Xiaozhang Zheng; Domenico Coppola; Srikumar Chellappan
Journal:  Sci Rep       Date:  2020-03-13       Impact factor: 4.379

9.  Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors.

Authors:  Zsófia Kutil; Jana Mikešová; Matthes Zessin; Marat Meleshin; Zora Nováková; Glenda Alquicer; Alan Kozikowski; Wolfgang Sippl; Cyril Bařinka; Mike Schutkowski
Journal:  ACS Omega       Date:  2019-11-15

Review 10.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Authors:  Guo Li; Yuan Tian; Wei-Guo Zhu
Journal:  Front Cell Dev Biol       Date:  2020-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.